Investigational MS Drug Safe, Effective at 18 Months
The potent, once-daily oral BTK inhibitor tolebrutinib showed encouraging safety and efficacy results in patients with multiple sclerosis through 72 weeks in a new long-term extension of a phase 2b trial.
Medscape Medical News
source https://www.medscape.com/viewarticle/969457?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/969457?src=rss
Comments
Post a Comment